H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies (PTN – Research Report) today and set a price target of $70.00. The company’s shares opened today at $2.13.
Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Krystal Biotech, and Onconova Therapeutics. According to TipRanks, Pantginis has an average return of -5.6% and a 33.40% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Palatin Technologies with a $60.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.49 and a one-year low of $1.82. Currently, Palatin Technologies has an average volume of 51.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Read More on PTN:
